Search Results

Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that data from its oncology portfolio will be presented at the 2023 European Hematology Association (EHA) Annual Meeting, to be held June 8 – 11, 2023, in Frankfurt, Germany, and virtually.

Cumulus Oncology, Europe’s first oncology-focused biotech company creation factory, announces the appointment of Catherine Lewis La Torre to its Board of Directors.

Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand therapies and synthetic lethality assets are also attracting attention.

Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced that study investigators will present data from the BRUIN Phase 1/2 trial of pirtobrutinib at the American Society of Hematology (ASH) Annual Meeting to be held December 10-13, 2022, in New Orleans, Louisiana, and virtually.

Kura Oncology, Inc. today announced its participation in Stifel 2024 Targeted Oncology Forum.

Loxo@Lilly, the oncology unit of Eli Lilly and Company (NYSE: LLY), today announced updated clinical data from the pirtobrutinib global Phase 1/2 BRUIN trial in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Richter transformation (RT), and Waldenström macroglobulinemia (WM).

Radionetics Oncology announced today the formation of a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals.

Diakonos Oncology Corporation, a clinical stage immuno-oncology company, announced that it will present at the Emerging Growth Conference on Wednesday, June 12.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024.

Mural Oncology plc, a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, shared data from ARTISTRY-3, a clinical trial designed to evaluate the effects of less frequent intravenous dosing of nemvaleukin alfa, in advance of the American Society of Clinical Oncology annual meeting taking place May 31-June 4 in Chicago.